Andy Scharenberg
Andy Scharenberg is Chief Executive Officer at Umoja Biopharma and Executive Partner at MPM BioImpact. He co-founded Generation Bio and Pregenen, and has served as Chief Scientific Officer at Casebia Therapeutics and Cellectis therapeutics. He has chaired scientific advisory boards at Alpine Immune Sciences and Generation Bio, and was a professor at the University of Washington and principal investigator at Seattle Children's Hospital and Research Institute.
Umoja Biopharma to Unveil UB-VV500, First In Vivo BCMA × GPRC5D CAR T Therapy for Multiple Myeloma at ASGCT
Umoja Biopharma will present UB-VV500, the industry’s first in vivo CAR T therapy combining BCMA and GPRC5D targeting multiple myeloma, at the ASGCT annual meeting, highlighting its novel dual-antigen approach and planned poster data release.
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
Umoja Biopharma appointed Dr. Marcela Maus and Dr. Athena Countouriotis to its board of directors, expanding leadership with experienced biotech and cell therapy experts.
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
See all 6 stories, episodes and videos about Andy Scharenberg.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
See all 10-
Umoja Biopharma Executive Officer, Director 2021–present, Co-founder & Chief Executive Officer 2019–present · current
-
MPM BioImpact Executive Partner 2019–present · current
-
Casebia Therapeutics Chief Scientific Officer 2017–2019 · past
Education
-
University of North Carolina School of Medicine MD, Medicine · 1991–1993